413 results about "Pancreatic cancer cell" patented technology

The present invention is directed to an antigen found on the surface of rat and human pancreatic cancer cells and provides antibodies of high specificity and selectivity to this antigen as well as hybridomas secreting the subject antibodies. Methods for both the diagnosis and treatment of pancreatic cancer are also provided. This tissue marker of pancreatic adenocarcinoma, an approximately 43.5 kD surface membrane protein designated PaCa-Ag1, is completely unexpressed in normal pancreas but abundantly expressed in pancreatic carcinoma cells. Moreover, a soluble form of PaCa-Ag1 exists, having a molecular weight about 36 to about 38 kD, that is readily identified in sera and other body fluids of pancreatic cancer patients, using a subject antibody.

The present inventors discovered that neural invasion is suppressed by inhibiting IL-6 in a model for neural invasion of pancreatic cancer, and completed the present invention. The present inventors also demonstrated that: an IL-6 receptor is expressed in cells of human pancreatic cancer cell lines; and IL-6 enhances the chemotactic and migratory activities and intracellular signaling of pancreatic cancer cells; and thus pancreatic cancer can be treated by inhibiting IL-6. Furthermore, the present inventors found that neural invasion of human pancreatic cancer can be suppressed, from the results of administering IL-6 inhibitors to neural invasion model mice.

The present invention includes a method of utilizing four peptide hormones to inhibit the growth of cancer(s). A dramatic decrease in the number of human pancreatic adenocarcinoma cells (i.e., the type of cancer with the highest mortality, with patients only surviving four months) was observed responsive to treatment. The application of the invention would be to utilize one or more of these peptide hormones alone and / or in combination to treat cancer. The ability of these peptide hormones to decrease the number of adenocarcinoma cells has implications for adenocarcinomas at other sites in the body with the majority of cancers of the breast, colon and prostate also being adenocarcinomas. Adenocarcinomas also occur in the lung and other tissues. Treatment of a wide variety of cancers in addition to adenocarcinomas is anticipated by the present invention.

The present invention relates to a novel gene, CaSm, that is highly expressed in cancer tissues and cell lines, especially pancreatic cancer. The full length cDNA of CaSm encodes a protein of 133 amino acids. CaSm contains the two Sm motifs found in the common snRNP proteins, with the greatest homology to the Sm G protein (60% similarity). The present invention further encompasses CaSm peptides, fusion proteins, host cell expression systems, antibodies to CaSm, antisense CaSM molecules, and compounds that modulate CaSm gene expression or CaSm activity. Antisense CaSm RNA is able to alter the transformed phenotype of pancreatic cancer cells by reducing their ability to form large colonies in soft agar when compared to untransfected cells. The present invention also encompasses methods for disease diagnosis, drug screening and the treatment of cancer.

The invention discloses attenuated salmonella typhimurium and application of a genetically engineered bacterium of the attenuated salmonella typhimurium to preparation of medicines for treating pancreatic cancer. The attenuated salmonella typhimurium has tumor targeting and a remarkable inhibiting effect on pancreatic cancer cells; the genetically engineered bacterium constructed by the attenuated salmonella typhimurium and a plasmid also has tumor targeting; the attenuated salmonella typhimurium with the plasmid with a clonal L-methioninase gene can continuously express L-methioninase on a tumor tissue to consume methionine and other nutrient substances to cause undernourishment and slow growth of tumor cells; therefore, both the attenuated salmonella typhimurium and the genetically engineered bacterium can be used for preparing the medicines for treating the pancreatic cancer.

The invention provides a veratramine degradation product veratrum fluorene aldehyde 1 and derivatives thereof. The invention uses steroidal alkaloid veratramine (A) as raw material and prepares veratrum fluorene aldehyde by oxidative degradation of m-chloroperoxybenzoic acid to obtain 20 derivative compounds of the veratrum fluorene aldehyde 1 after further oxidation, reduction and condensation reaction. The 20 compounds of the invention have good inhibitory activity on cancer cells, wherein the compounds 1, 2, 5, 8, 13 and 17 have good inhibitory activity on cells of human pancreatic cancer cells BxPC-3 and SW1990, small-cell lung cancer cells NCI-H446, human colorectal cancer LOVO and the like, and the inhibitory activity of the compound veratrum fluorene aldehyde 1 is the most significant.

The present invention relates to methods and compositions for inhibiting proliferation and inducing cell death in a population of cancer cells by (i) increasing the amount of the differentiation associated protein MDA-7, and (ii) decreasing RAS activity within the population. It is based, at least in part, on the discovery that decreasing expression of a mutated, activated K-ras gene, together with introducing an expressible mda-7 gene, in pancreatic cancer cells had a synergistic growth-inhibitory and anti-survival effect, and abolished tumorigenicity of the cells in athymic nude mice. The methods of the invention may be directed to the therapy of pancreatic cancer and other malignancies.

AnnexinA2 (ANXA2), a member of the Annexin family of calcium-dependent, phospholipid binding proteins, is one of a panel of identified antigens recognized by the post-vaccination sera of patients who demonstrated prolonged disease-free survival following multiple vaccinations. AnnexinA2 is abundantly expressed in pancreatic adenocarcinomas and cell surface / membrane AnnexinA2 increases with the progression from premalignant lesions to invasive pancreatic adenocarcinomas. The cytoplasmic to cell surface translocation of AnnexinA2 expression is critical for pancreatic cancer cell invasion. In addition, phosphorylation of AnnexinA2 at Tyrosine 23 is important for its localization to the cell surface and for the invasion of pancreatic cancer cells. Finally, loss of AnnexinA2 leads to the loss of the Epithelial-Mesenchymal Transition.

The present invention relates to the use of cytoxicity based on the effector function of anti-EphA4 antibodies. Specifically, the present invention provides methods and pharmaceutical compositions that comprise an anti-EphA4 antibody as an active ingredient for damaging EphA4-expressing cells using antibody effector function. Since EphA4 is strongly expressed in pancreatic cancer cells, the present invention is particularly useful in pancreatic cancer therapies.

The invention provides a quantitative realtime RT-PCR assay for detection of metastatic breast, gastric, pancreas or colon cancer cells or metastatic melanoma. The assay allows to predict disease recurrence and survival in patients with AJCC stage I and II, and III disease using multimarker panels. The method for detecting metastatic melanoma cells utilizes panels of markers selected from a group consisting of MAGE-A3, GalNAcT, MART-1, PAX3, Mitf, TRP-2, and Tyrosinase. The method for detecting metastatic breast, gastric, pancreas or colon cancer cells in paraffin-embedded samples utilizes panels of markers selected from a group consisting of C-Met, MAGE-A3, Stanniocalcin-1, mammoglobin, HSP27, GalNAcT, CK20, and β-HCG.

The present invention relates to a method for inhibiting tumor growth, in particular to the method using dehydrosulphurenic acid to inhibit the growth of leukemia cell or pancreatic cancer cell by a compound extracted and purified from Antrodia cinnamomea. Dehydrosulphurenic acid of the invention can be used as a pharmaceutical composition to inhibit the tumor growth of leukemia or pancreatic cancer.

The invention belongs to microbiological animal cell system fiels, which in detail relates to a pancreatic cancer hepatic metastases clone SW1990HM with hepatic metastases potence. The clone possesses special transition phenotype, and if inoculated to mouse spleen, it will result to 100% hepatic metastases, and it is the first human pancreatic cancer clone with hepatic metastases potence in domestic. The genetic backgroud of said clone strain is the same to that of origianl cell, and it is characterized by strong invasiveness, high transmission efficiency and large transmission range. The invention provides proper experimental platform for further researching, preventing and treating pancreatic cancer hepatic metastases.

The present invention relates to the use of cytoxicity based on the effector function of anti-EphA4 antibodies. Specifically, the present invention provides methods and pharmaceutical compositions that comprise an anti-EphA4 antibody as an active ingredient for damaging EphA4-expressing cells using antibody effector function. Since EphA4 is strongly expressed in pancreatic cancer cells, the present invention is particularly useful in pancreatic cancer therapies.

AnnexinA2 (ANXA2), a member of the Annexin family of calcium-dependent, phospholipid binding proteins, is one of a panel of identified antigens recognized by the post-vaccination sera of patients who demonstrated prolonged disease-free survival following multiple vaccinations. AnnexinA2 is abundantly expressed in pancreatic adenocarcinomas and cell surface / membrane AnnexinA2 increases with the progression from premalignant lesions to invasive pancreatic adenocarcinomas. The cytoplasmic to cell surface translocation of AnnexinA2 expression is critical for pancreatic cancer cell invasion. In addition, phosphorylation of AnnexinA2 at Tyrosine 23 is important for its localization to the cell surface and for the invasion of pancreatic cancer cells. Finally, loss of AnnexinA2 leads to the loss of the Epithelial-Mesenchymal Transition.

Disclosed are cyanoacrylate polymer particles which comprise an amino acid(s) and have an average particle diameter of less than 1000 nm. The amino acid-containing particles according to the present invention can kill cancer cells by inducing apoptosis-like cell death. The particles have an especially high affinity for cell lines derived from lymphomas such as T-cell lymphoma and B-cell lymphoma. The particles can also exhibit an antiproliferative effect against some kinds of pancreatic cancer-derived cell lines. Therefore, the particles according to the present invention are useful for prevention and / or treatment of cancers.

The invention belongs to the technical field of chemical and pharmaceutical industry and particularly relates to the application of mogrol H9 for preparing antitumor drugs. The invention provides the application of mogrol H9 for preparing antitumor medicaments. The tumor cell can be liver cancer cell, leukaemia cell, cervical carcinoma cell, lung adenocarcinoma cell, stomach cancer cell, breast cancer cell or pancreatic cancer cell. The compound H9 is a natural product, has less toxic and adverse effects, high bioavailability and stable property, and is significant in clinical use. The small molecule compound is developed as a new antitumor drug or antitumor effective component, has an obvious antitumor effect, is green and environment-friendly, and provides a new approach to treatment and healing of tumors.

Methods are disclosed for treating neoplastic disorders, such as pancreatic cancer, using tocotrienols; namely, gamma-tocotrienol and delta tocotrienol. The antitumorogenic effects of these compounds are shown both in vitro and in vivo using several human pancreatic cancer cell lines and MIA-PACA2 human pancreatic cancer cells xenografted in nude mice. Also disclosed are methods of testing the efficacy of potential chemotherapeutic agents by measuring their effect on surrogate endpoint biomarkers, such as Ki-67 and p27. Associated compounds are also disclosed.

The present invention relates to a novel application of a compound. The compound 4-hydroxy-2,3-dimethoxy-6-methyl-5-(3,7,11-trimethyl-dodeca-2,6,10-trienyl)-cyclohex-2-enone of the invention is isolated and purified from the extracts of Antrodia camphorata, which can be applied for inhibiting the survival of pancreatic cancer cells and be used as a pharmaceutical composition to inhibit the pancreatic tumor growth.

The present invention revealed that AT-264 suppresses cell growth through its inhibitory effect on PepT1 activity. Furthermore, as a result of examining whether AT-264 comprises the effect of inhibiting the cell growth of human pancreatic cancer cell line AsPC-1, the present invention revealed that cell growth is similarly suppressed. These findings show that cell growth can be suppressed by inhibiting the activity of peptide transporters. Suppression of peptide transporter activity can be considered to be an important indicator in the development of growth inhibitors for cancer cells and such.

The invention belongs to the technical field of biology and relates to an early pancreatic cancer marker and a detection method thereof. A biological micromolecule which can be used for early pancreatic cancer molecular diagnosis and treatment is developed on the basis of expression intensity differences of various micro ribonucleic acids in early pancreatic cancer cells. The early pancreatic cancer marker has advantages of wide detection pedigree, high sensitivity, high specificity, low detection cost, convenience in material acquisition, easiness in sample storage and the like. The method can be widely applied to pancreatic cancer early screening and prognosis and the like, low specificity and low sensitivity due to hard-to-overcome individual differences caused by intrinsic instabilityof single markers or biomarkers clinically and extensively applied at present are improved, the early pancreatic cancer clinical detection rate is remarkably increased, the pancreatic cancer misdiagnosis rate and missed diagnosis rate are decreased, and the method is an effective means of early pancreatic cancer detection.

The invention relates to an anticancer medicine which is a lanosterol derivative. The compound has an anticancer effect, and can inhibit the growths of lung cancer cells, liver cells, mammary gland cells, brain cancer cells, and pancreatic cancer cells. The medicine is a compound with a general formula of (I), (II), (III), or (IV). The invention also provides an application of the compound or pharmaceutically acceptable salt thereof in preparing medicines used for treating cancers. The medicine can be used independently, and can be used in combination. Especially, the medicine can be used in combination with gemcitabine or nexavar. The medicine can be used in treating cancers such as lung cancer, liver cancer, pancreatic cancer, breast cancer, brain cancer, and the like.

A polypeptide M204C4 for suppressing the activity of gelatinase A (MMP-2) is composed of the amino acid sequence shown by HNWTRWLLHPDRGGGS is disclosed. It can also suppress the invasion and transfer of external pancreas cancer cells PANC01 and CFPAC-1. Its preparing process includes such steps as affinity screening and reproduction of bacteriophage several times to obtain the bacteriophage with specific binding to MMP-2, coating, cloning and monoclonal screening with fluorescent screening reagent kit.

The invention provides a pancreatic cancer pathological image classification method based on self-attention feature fusion, and the method comprises the steps: firstly, employing a convolutional neural network model to extract the features of an input image, and carrying out the feature embedding of a feature map outputted by the final stage of the convolutional neural network model; secondly, feature maps output by the convolutional neural network model at different stages are subjected to attention analysis to obtain attention guidance information; then, a Transform model based on self-attention feature modeling and a self-attention feature fusion network model are constructed; and finally, training the self-attention feature fusion network model for multiple rounds, measuring and determining the model corresponding to the round with the optimal result by using the pathological image of the verification set, thereby constructing a pancreatic cell cancerization classification diagnosis system, and judging whether the pancreatic cell pathological image is a pancreatic cancer cell image or a normal cell image through the system. According to the invention, global modeling is carried out on the convolutional neural network features by applying a self-attention technology and an attention analysis mechanism so as to realize high-precision rapid on-site evaluation of pancreatic cancer.

This invention relates to a pharmaceutical composition for inhibiting the growth and / or metastasis of invasive pancreatic cancer in a subject, comprising a molecular-targeted anticancer agent and a pharmaceutically acceptable carrier, wherein the molecular-targeted anticancer agent is a conjugate of a toxin or cytotoxic agent and an antibody or fragment thereof which immunologically and specifically binds to a cell-surface folate receptor β (FRβ) protein of an FRβ (+) macrophage that exists around pancreatic cancer cells at the invasive front, and to a diagnostic agent and kit for determining the degree of malignancy of pancreatic cancer or the presence of invasive pancreatic cancer, characterized by determining that the cancer tissue is invasive and metastatic when FRβ (+) macrophage is distributed around pancreatic cancer cells at the invasive front.

The main drawback in the use of most nucleoside anticancer agents originates from their hydrophilic nature, of which property requires a high and frequent dosage for an intravenous administration. Unlike other nucleoside anti-tumor agents, troxacitabine appears to predominantly enter tumor cells by passive diffusion rather then by using nucleoside transporters, although this may be model dependent. Accordingly, in the present work, a small library of twenty troxacitabine prodrugs has been synthesized using a parallel approach in order to evaluate the relationship between the lipophilicity of the prodrugs and their antitumor activity. Biological evaluation of the prodrugs on two non-small cell lung cancer cell lines (A549 and SW1573) and in pancreatic cell lines clearly showed better antitumor activity than that of troxacitabine, with IC50 values in the nanomolar range.

A method for treating cancer by killing selected tumor cells such as human breast, non-small cell lung cancer cells, pancreatic cancer cells, osteosarcoma cancer cells, and glioblastoma cells, includes administering to a patient in need of treatment, an effective amount of at least one mannose analog such as 2-DG or 2-FM or 2-CM. The killing is believed to be due to an interference with glycosylation. A theranostic method includes determining whether a patient. cancer tumor sample comprises cells sensitive to killing to at least one mannose analog due to an interference with glycosylation.

Cyclic peptide compounds and derivatives thereof having antitumor activity as shown by treatment of human melanoma, pancreatic, breast, prostate cancer cells.

The invention belongs to the field of microorganism animal cell lines, and particularly relates to a pancreatic cancer cell line with lymphatic channel high migration activity. According to the pancreatic cancer cell line with the lymphatic channel high migration activity, a human pancreatic cancer BxPC-3 cell line is adopted as source cells, by means of a nude mouse palmula subcutaneous vaccinization method, lymphatic metastasis oncocyte sunlines with different migration potentialities are separated from matrilineal BxPC-3 cells, a pancreatic cancer cell line BxPC-3-LN with the lymphatic channel high migration activity is screened out through experiments inside and outside human bodies, a storage number is CGMCC NO.5421, and the storage date is October 28th, 2011. The pancreatic cancer cell line with the lymphatic channel high migration activity is the same as the matrilineal BxPC-3 cells in the genetic background, is characterized by being strong in invasiveness, high in migration efficiency and concentrated in migration, provides a suitable experimental platform for research on pancreatic cancer migration mechanism and the screening of antineoplastic drugs, and has very important significance and wide application prospects.

The invention discloses a tetrandrine derivative with antitumor activity and a preparation method thereof. The structural formula of the compound is shown in the specification. The preparation method comprises the following steps: dissolving bisbenzylisoquinoline compound serving as raw material in certain solvent; adding an alkali reagent and a reactant Y, and mixing; reacting for 0.1 to 72 hours under temperature of -20 to 300 DEG C; neutralizing the reacted solution with acid, and then separating and purifying to prepare the objective product. The tetrandrine derivative prepared by the invention can well inhibit proliferation of human hepatoma cell line HepG2 and pancreatic cancer cell SW1990, and can be used for preparing antitumor medicines.

The present invention relates to a method for inhibiting tumor growth, in particular to the method using dehydrosulphurenic acid to inhibit the growth of leukemia cell or pancreatic cancer cell by a compound extracted and purified from Antrodia cinnamomea. Dehydrosulphurenic acid of the invention can be used as a pharmaceutical composition to inhibit the tumor growth of leukemia or pancreatic cancer.